Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02566525
Other study ID # 2015-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2015
Est. completion date December 2016

Study information

Verified date July 2021
Source CytoSorbents, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, multi-center, randomized, feasibility clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care and treatment with the CytoSorb® device.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date December 2016
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Elective, cardiac surgery requiring cardiopulmonary bypass with anticipated duration of >180 minutes Exclusion Criteria: - Platelet count < 20,000/ uL - Body mass index <18 - Pregnant women - Life expectancy of <14 days - End stage organ disease - Active infection - Undergoing cardiac transplant or ventricular assist device explant, isolated primary coronary artery bypass grafting (CABG) or single valve procedure - Contraindication to anticoagulation with heparin - Declined informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CytoSorb
Cytosorb device use during cardiopulmonary bypass

Locations

Country Name City State
United States University of Maryland Baltimore Maryland
United States Cooper University Hospital Camden New Jersey
United States Baylor College of Medicine Houston Texas
United States University of Kentucky Lexington Kentucky
United States Columbia University New York New York
United States University of Pennsylvania Philadelphia Pennsylvania
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania
United States Baystate Medical Springfield Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
CytoSorbents, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Complement Factor C3a - 2 Hours Post Start of CPB Change in complement factor C3a - Sampling at 2 hours post start of CPB 2 hours post start of cardiac bypass
Other Change in Complement Factor C3a - 3 Hours Post Start of CPB Change in complement factor C3a - Sampling at 3 hours post start of CPB 3 hours post start of CPB
Other Change in Complement Factor C5a - 2 Hours Post Start of CPB Change in complement factor C5a - Sampling at 2 hours post start of CPB, change from baseline 2 hours post start of cardiac bypass
Primary Assessment of Serious Device Related Adverse Events The primary safety endpoint of this trial was to determine the product safety profile through the assessment of serious device related AEs through discharge from the ICU. From time of enrollment through ICU discharge (e.g. ICU stay of approximately 4 days)
Secondary Time in the ICU Days in ICU, Post Surgery From the end of cardiopulmonary bypass procedure through ICU discharge (e.g. ICU stay of approximately 4 days)
Secondary 30 Day All Cause Mortality Mortality within 30 Days of Surgery From time of enrollment through 30 days post procedure
Secondary Adverse Event Rates Total number of Serious Adverse Events through 30 days
See also
  Status Clinical Trial Phase
Completed NCT02838524 - Acceptable Range of Inspiratory Effort During Mechanical Ventilation
Completed NCT00879931 - Influence of Corticoids on Renal Function in Cardiac Surgery Phase 2
Recruiting NCT05662501 - Pleiades Safety and Feasibility Study N/A
Completed NCT02407873 - Prognostic Impact of Frailty Assessed by Edmondon in Elderly Patient Undergoing Cardiac Surgery N/A
Not yet recruiting NCT01418521 - Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac Surgery Phase 4
Completed NCT01748266 - Microcirculation of the Thenar Eminence N/A
Terminated NCT03384875 - CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery N/A